Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Open-label Study in Two Parts, Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Clinical Activity of CCW702 in Patients With Metastatic, Castration Resistant Prostate Adenocarcinoma

NCT04077021 is registered in ClinicalTrials.gov with Calibr, a division of Scripps Research as lead sponsor.

NCT NCT04077021
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04077021 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Open-label Study in Two Parts, Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Clinical Activity of CCW702 in Patients With Metastatic, Castration Resistant Prostate Adenocarcinoma
Lead sponsor
Calibr, a division of Scripps Research
Phase
Phase 1
Overall status
Terminated
Start date
July 17, 2020
Completion date
October 21, 2022
Enrollment
22 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic castration-resistant prostate adenocarcinoma